PH12013500848B1 - Trpv1 antagonists and uses thereof - Google Patents

Trpv1 antagonists and uses thereof

Info

Publication number: PH12013500848B1
Authority: PH; Philippines
Prior art keywords: formula; pharmaceutically acceptable; compound; effective amount; trpv1 antagonists
Prior art date: 2007-04-27

Application number

PH12013500848A

Other languages

English (en)

Other versions

PH12013500848A1 (en

Inventor

Tafesse Laykea

Kurose Noriyuki

Original Assignee

Purdue Pharma Lp

Shionogi & Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-04-27

Filing date

2013-04-26

Publication date

2015-05-18

2013-04-26 Application filed by Purdue Pharma Lp, Shionogi & Co filed Critical Purdue Pharma Lp

2015-05-18 Publication of PH12013500848A1 publication Critical patent/PH12013500848A1/en

2015-05-18 Publication of PH12013500848B1 publication Critical patent/PH12013500848B1/en

Links

101150016206 Trpv1 gene Proteins 0.000 title 1
239000005557 antagonist Substances 0.000 title 1
150000001875 compounds Chemical class 0.000 abstract 3
208000025865 Ulcer Diseases 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
231100000397 ulcer Toxicity 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/61—Halogen atoms or nitro radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurosurgery (AREA)
Urology & Nephrology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Pain & Pain Management (AREA)
Epidemiology (AREA)
Anesthesiology (AREA)
Rheumatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Pyridine Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Hydrogenated Pyridines (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

PH12013500848A 2007-04-27 2013-04-26 Trpv1 antagonists and uses thereof PH12013500848B1 (en)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US92666107P	2007-04-27	2007-04-27
US93003607P	2007-05-11	2007-05-11
US93700307P	2007-06-21	2007-06-21
US96240907P	2007-07-27	2007-07-27
PCT/IB2008/001069 WO2008132600A2 (en)	2007-04-27	2008-04-25	Trpv1 antagonists and uses thereof

Publications (2)

Publication Number	Publication Date
PH12013500848A1 PH12013500848A1 (en)	2015-05-18
PH12013500848B1 true PH12013500848B1 (en)	2015-05-18

Family

ID=39688846

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PH12013500848A PH12013500848B1 (en)	2007-04-27	2013-04-26	Trpv1 antagonists and uses thereof

Country Status (27)

Country	Link
US (8)	US20090176796A1 (2)
EP (3)	EP2142529B1 (2)
JP (2)	JP5462784B2 (2)
KR (2)	KR20130004524A (2)
CN (1)	CN101932570B (2)
AR (1)	AR066146A1 (2)
AU (1)	AU2008243874B2 (2)
BR (1)	BRPI0809795A2 (2)
CA (3)	CA2685266C (2)
CO (1)	CO6241153A2 (2)
CY (1)	CY1115262T1 (2)
DK (1)	DK2142529T3 (2)
ES (2)	ES2571533T3 (2)
HR (1)	HRP20140279T1 (2)
IL (2)	IL201688A (2)
ME (1)	ME02123B (2)
MX (1)	MX2009011600A (2)
MY (1)	MY148657A (2)
NZ (1)	NZ580266A (2)
PE (2)	PE20130325A1 (2)
PH (1)	PH12013500848B1 (2)
PL (1)	PL2142529T3 (2)
PT (1)	PT2142529E (2)
RS (1)	RS53212B (2)
TW (1)	TWI362930B (2)
UY (1)	UY31050A1 (2)
WO (1)	WO2008132600A2 (2)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2002060446A1 (fr)	2001-01-29	2002-08-08	Shionogi & Co., Ltd.	Preparation medicamenteuse contenant du 5-methyle-1-phenyle-2-(1h)-pyridone en tant que principe actif
CA2685266C (en) *	2007-04-27	2014-01-28	Purdue Pharma L.P.	Trpv1 antagonists and uses thereof for the treatment of prevention of pain, ui and ulcer, ibd, or ibs in an animal
US8546388B2 (en) *	2008-10-24	2013-10-01	Purdue Pharma L.P.	Heterocyclic TRPV1 receptor ligands
US8703962B2 (en) *	2008-10-24	2014-04-22	Purdue Pharma L.P.	Monocyclic compounds and their use as TRPV1 ligands
US8759362B2 (en) *	2008-10-24	2014-06-24	Purdue Pharma L.P.	Bicycloheteroaryl compounds and their use as TRPV1 ligands
US8431576B2 (en)	2009-06-25	2013-04-30	Alkermes Pharma Ireland Limited	Heterocyclic compounds for the treatment of neurological and psychological disorders
ES2834973T3 (es)	2010-05-04	2021-06-21	Alkermes Pharma Ireland Ltd	Procedimiento de síntesis de compuestos de lactama oxidada
CA3007787C (en)	2010-06-03	2020-03-10	Pharmacyclics Llc	The use of inhibitors of bruton's tyrosine kinase (btk)
US8921373B2 (en)	2010-06-22	2014-12-30	Shionogi & Co., Ltd.	Compounds having TRPV1 antagonistic activity and uses thereof
ES2691671T3 (es)	2010-06-24	2018-11-28	Alkermes Pharma Ireland Limited	Profármacos de compuestos NH-acídicos: derivados de éster, carbonato, carbamato y fosfonato
US9598447B2 (en)	2010-12-22	2017-03-21	Purdue Pharma L.P.	Phosphorus-substituted quinoxaline-type piperidine compounds and uses thereof
JP6130827B2 (ja)	2011-05-17	2017-05-17	塩野義製薬株式会社	ヘテロ環化合物
PE20141531A1 (es) *	2011-06-22	2014-10-23	Purdue Pharma Lp	Antagonistas de trpv1 que incluyen sustituyentes dihidroxi y sus usos
AU2012293417A1 (en)	2011-08-10	2013-05-02	Purdue Pharma L.P.	TRPV1 antagonists including dihydroxy substituent and uses thereof
WO2013043002A1 (en) *	2011-09-23	2013-03-28	Yuhan Corporation	Imide-containing benzothiazole derivative or its salt and pharmaceutical composition comprising the same
KR20210033067A (ko)	2012-06-04	2021-03-25	파마싸이클릭스 엘엘씨	브루톤 타이로신 키나아제 저해제의 결정 형태
CN104704129A (zh)	2012-07-24	2015-06-10	药品循环公司	与对布鲁顿酪氨酸激酶(btk)抑制剂的抗性相关的突变
JP6249517B2 (ja) *	2012-11-08	2017-12-20	花王株式会社	体感温度低減用外用剤
EP2774919A1 (en) *	2013-03-06	2014-09-10	Pharmeste S.R.L. In Liquidazione	Novel sulfonamide TRPA1 receptor antagonists
US20160213659A1 (en) *	2013-09-24	2016-07-28	George Sylvestre	Treatment of burn pain by trpv1 modulators
JP6308881B2 (ja) *	2014-06-11	2018-04-11	保土谷化学工業株式会社	電荷制御剤およびそれを用いたトナー
IL315294A (en)	2015-03-03	2024-10-01	Pharmacyclics Llc	Pharmaceutical formulations of bruton's tyrosine kinase inhibitor
CA2937365C (en)	2016-03-29	2018-09-18	F. Hoffmann-La Roche Ag	Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
CN113292485B (zh) *	2021-06-08	2023-10-27	河南大学	苄基哌嗪脲类trpv1拮抗和mor激动双靶点药物及制备方法和应用
CN120513091A (zh)	2022-10-31	2025-08-19	盐野义制药株式会社	作为trpv1拮抗剂的吡啶衍生物的用途

Family Cites Families (149)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3536809A (en)	1969-02-17	1970-10-27	Alza Corp	Medication method
US3598123A (en) *	1969-04-01	1971-08-10	Alza Corp	Bandage for administering drugs
US3845770A (en) *	1972-06-05	1974-11-05	Alza Corp	Osmatic dispensing device for releasing beneficial agent
US3916899A (en) *	1973-04-25	1975-11-04	Alza Corp	Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en)	1976-02-02	1977-02-22	Alza Corporation	Osmotic system having laminar arrangement for programming delivery of active agent
US4409229A (en) *	1977-12-02	1983-10-11	Hoechst-Roussel Pharmaceuticals, Inc.	Antidepressive and tranquilizing substituted 1,3-dihydrospiro[benzo(c)thiophene]s
IE58110B1 (en)	1984-10-30	1993-07-14	Elan Corp Plc	Controlled release powder and process for its preparation
DE3440141A1 (de)	1984-11-02	1986-05-07	Heiner Dipl.-Chem. Dr. 8000 München Eckert	Verwendung von kohlensaeure-bis-trichlormethylester als proreagens fuer phosgen
JPH0680054B2 (ja)	1985-06-19	1994-10-12	吉富製薬株式会社	ピペリジン誘導体
JPS6289679U (2)	1985-11-22	1987-06-08
US4797419A (en)	1986-11-03	1989-01-10	Warner-Lambert Company	Method of treating the symptoms of senile cognitive decline employing di- or trisubstituted urea cholinergic agents
US4866197A (en)	1987-12-23	1989-09-12	American Home Products Corporation	Production of N-((2-alkoxy-6-methoxy-5-(trifluoromethyl)-1-naphthalenyl)carbonyl)-N-methylglycine esters
US5073543A (en) *	1988-07-21	1991-12-17	G. D. Searle & Co.	Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
DE3905364A1 (de) *	1989-02-22	1990-08-23	Hoechst Ag	Substituierte pyrimidin-derivate, verfahren zu ihrer herstellung und ihre verwendung als tool
IT1229203B (it)	1989-03-22	1991-07-25	Bioresearch Spa	Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) *	1989-11-07	1992-06-09	Merck & Co., Inc.	Swelling modulated polymeric drug delivery device
US5733566A (en)	1990-05-15	1998-03-31	Alkermes Controlled Therapeutics Inc. Ii	Controlled release of antiparasitic agents in animals
PT97888B (pt) *	1990-06-07	1998-12-31	Zeneca Ltd	Processo para a preparacao de compostos heterociclicos derivados de indol e de composicoes farmaceuticas que os contem
US5698155A (en)	1991-05-31	1997-12-16	Gs Technologies, Inc.	Method for the manufacture of pharmaceutical cellulose capsules
US5580578A (en)	1992-01-27	1996-12-03	Euro-Celtique, S.A.	Controlled release formulations coated with aqueous dispersions of acrylic polymers
JP3191429B2 (ja)	1992-09-02	2001-07-23	富士通テン株式会社	電子機器の挿排装置
US5728704A (en) *	1992-09-28	1998-03-17	Pfizer Inc.	Substituted pyridmidines for control of diabetic complications
DE4234295A1 (de) *	1992-10-12	1994-04-14	Thomae Gmbh Dr K	Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US5591767A (en) *	1993-01-25	1997-01-07	Pharmetrix Corporation	Liquid reservoir transdermal patch for the administration of ketorolac
DE4302051A1 (de)	1993-01-26	1994-07-28	Thomae Gmbh Dr K	5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
IT1270594B (it)	1994-07-07	1997-05-07	Recordati Chem Pharm	Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
DE19514313A1 (de)	1994-08-03	1996-02-08	Bayer Ag	Benzoxazolyl- und Benzothiazolyloxazolidinone
ES2247604T3 (es)	1995-06-12	2006-03-01	G.D. SEARLE & CO.	Composiciones que comprenden un inhibidor de ciclooxigenasa-2 y un inhibidor de 5-lipoxigenasa.
TR199800409T1 (xx) *	1995-09-07	1998-05-21	F.Hoffmann-La Roche Ag	Kalp ve b�brek yetersizli�inin tedavii�in yeni 4-(oksialkoksifenil)-3-oksi-piperidinler
US5837716A (en) *	1995-11-13	1998-11-17	Albany Medical College	Analgesic heterocyclic compounds
FR2744448B1 (fr)	1996-02-02	1998-04-24	Pf Medicament	Nouvelles piperidines derivees d'aryl piperazine, ainsi que leur procede de preparation, les compositions pharmaceutiques et leur utilisation comme medicaments
US5891889A (en) *	1996-04-03	1999-04-06	Merck & Co., Inc.	Inhibitors of farnesyl-protein transferase
EP0944388A4 (en)	1996-04-03	2001-08-16	Merck & Co Inc	INHIBITORS OF FARNESYL PROTEIN TRANSFERASE
US5948786A (en) *	1996-04-12	1999-09-07	Sumitomo Pharmaceuticals Company, Limited	Piperidinylpyrimidine derivatives
US5990107A (en) *	1996-06-28	1999-11-23	Merck & Co., Inc.	Fibrinogen receptor antagonist prodrugs
US5854245A (en)	1996-06-28	1998-12-29	Merck & Co., Inc.	Fibrinogen receptor antagonists
US5798360A (en)	1996-08-01	1998-08-25	Isis Pharmaceuticals, Inc.	N-(aminoalkyl)- and/or N-(amidoalkyl)- dinitrogen heterocyclic compositions
FR2758328B1 (fr)	1997-01-15	1999-04-02	Pf Medicament	Nouvelles amines aromatiques derivees d'amines cycliques utiles comme medicaments
FR2758327B1 (fr)	1997-01-15	1999-04-02	Pf Medicament	Nouvelles arylpiperazines derivees de piperidine
WO1999009140A1 (en) *	1997-08-20	1999-02-25	The Regents Of The University Of California	Nucleic acid sequences encoding capsaicin receptor and capsaicin receptor-related polypeptides and uses thereof
JPH11199573A (ja)	1998-01-07	1999-07-27	Yamanouchi Pharmaceut Co Ltd	５ｈｔ３受容体作動薬及び新規ベンゾチアゾール誘導体
TR200002182T2 (tr) *	1998-01-27	2000-12-21	Aventis Pharmaceuticals Products Inc.	İkame edilmiş aksozaherosayklil faktör xa inhibitörleri
EP0943683A1 (en) *	1998-03-10	1999-09-22	Smithkline Beecham Plc	Human vanilloid receptor homologue Vanilrep1
AU4685699A (en)	1998-06-19	2000-01-05	Eli Lilly And Company	Preparation of heteroaryl compounds
AU4395399A (en)	1998-07-02	2000-01-24	Sankyo Company Limited	Five-membered heteroaryl compounds
CN1129581C (zh) *	1998-09-22	2003-12-03	山之内制药株式会社	氰基苯基衍生物
AU3215500A (en)	1999-01-25	2000-08-07	Smithkline Beecham Corporation	Compounds and methods
GB9907097D0 (en) *	1999-03-26	1999-05-19	Novartis Ag	Organic compounds
PL350884A1 (en) *	1999-04-01	2003-02-10	Pfizer Prod Inc	Aminopyrimidines as sorbitol dehydrogenase inhibitors
EP1183238A1 (en)	1999-05-17	2002-03-06	Eli Lilly And Company	Metabotropic glutamate receptor antagonists
GB9912411D0 (en) *	1999-05-28	1999-07-28	Pfizer Ltd	Compounds useful in therapy
DE19934799B4 (de) *	1999-07-28	2008-01-24	Az Electronic Materials (Germany) Gmbh	Chiral-smektische Flüssigkristallmischung und ihre Verwendung in Aktivmatrix-Displays mit hohen Kontrastwerten
US7343017B2 (en) *	1999-08-26	2008-03-11	American Technology Corporation	System for playback of pre-encoded signals through a parametric loudspeaker system
AU7514700A (en)	1999-09-07	2001-04-10	Syngenta Participations Ag	Cyanopiperidines
US6887870B1 (en)	1999-10-12	2005-05-03	Bristol-Myers Squibb Company	Heterocyclic sodium/proton exchange inhibitors and method
KR20020084116A (ko)	2000-02-07	2002-11-04	애보트 게엠베하 운트 콤파니 카게	2-벤조티아졸릴 우레아 유도체 및 이의 단백질 키나제억제제로서의 용도
AU2001255600A1 (en)	2000-04-25	2001-11-07	Pharmacia Corporation	Regioselective synthesis of 3,4-di(carbocyclyl or heterocyclyl)thiophenes
AU2001281817B2 (en) *	2000-06-21	2005-11-24	F. Hoffmann-La Roche Ag	Benzothiazole derivatives
AR028782A1 (es) *	2000-07-05	2003-05-21	Taisho Pharmaceutical Co Ltd	Derivados heterociclicos tetrahidropiridino o piperidino
DE60132456T2 (de) *	2000-07-13	2009-01-08	Merck Patent Gmbh	Chirale verbindungen i
EP1301484A2 (en) *	2000-07-20	2003-04-16	Neurogen Corporation	Capsaicin receptor ligands
CA2426592A1 (en) *	2000-10-18	2002-04-25	Pfizer Products Inc.	Combination of statins and sorbitol dehydrogenase inhibitors
CA2430298A1 (en) *	2000-11-30	2002-06-06	Banavara Lakshman Mylari	Combination of gaba agonists and sorbitol dehydrogenase inhibitors
WO2002048098A1 (en)	2000-12-15	2002-06-20	Japan Science And Technology Corporation	Arylbis (perfluoroalkylsulfonyl) methane, metal salt of the same, and processes for producing these
US7193113B2 (en) *	2000-12-15	2007-03-20	Japan Science And Technology Corporation	Arylbis(perfluoroalkylsulfonyl) methane and metallic salt thereof, and methods for producing the same
US20030232996A1 (en) *	2001-04-20	2003-12-18	Brown David L	Regioselective synthesis of 3,4-di{(carboclyl or heterocyclyl)thiophenes
ATE409181T1 (de)	2001-05-08	2008-10-15	Univ Yale	Proteomimetische verbindungen und verfahren
US20040038982A1 (en) *	2001-07-13	2004-02-26	Bondinell William E.	Compounds and methods
JP2003095951A (ja)	2001-09-25	2003-04-03	Sumitomo Pharmaceut Co Ltd	慢性関節リウマチ治療剤
US20040259912A1 (en)	2001-09-28	2004-12-23	Takahiro Matsumoto	Benzine derivatives, process for preparing the same and use thereof
WO2003053922A2 (en)	2001-12-19	2003-07-03	Merck & Co., Inc.	Heteroaryl substituted imidazole modulators of metabotropic glutamate receptor-5
US7390813B1 (en) *	2001-12-21	2008-06-24	Xenon Pharmaceuticals Inc.	Pyridylpiperazines and aminonicotinamides and their use as therapeutic agents
US20050119251A1 (en) *	2001-12-21	2005-06-02	Jian-Min Fu	Nicotinamide derivatives and their use as therapeutic agents
JP2003192673A (ja)	2001-12-27	2003-07-09	Bayer Ag	ピペラジンカルボキシアミド誘導体
US7071335B2 (en) *	2002-02-01	2006-07-04	Euro-Celtique S.A.	2-pyridinyl-1-piperazine therapeutic agents useful for treating pain
AU2003245773A1 (en) *	2002-02-15	2003-09-04	Glaxo Group Limited	Vanilloid receptor modulators
US6974818B2 (en)	2002-03-01	2005-12-13	Euro-Celtique S.A.	1,2,5-thiadiazol-3-YL-piperazine therapeutic agents useful for treating pain
MXPA04008797A (es) *	2002-03-13	2004-11-26	Janssen Pharmaceutica Nv	Inhibidores de histona desacetilasa.
GB0209715D0 (en) *	2002-04-27	2002-06-05	Astrazeneca Ab	Chemical compounds
CN1150176C (zh) *	2002-05-22	2004-05-19	上海医药工业研究院	芳烷酮哌嗪衍生物及其应用
WO2003099266A2 (en) *	2002-05-23	2003-12-04	Abbott Laboratories	Acetamides and benzamides that are useful in treating sexual dysfunction
JPWO2004002531A1 (ja) *	2002-06-26	2005-10-27	小野薬品工業株式会社	血管の収縮または拡張による疾患治療剤
EA200500114A1 (ru) *	2002-06-28	2005-06-30	Еуро-Селтик, С. А.	Терапевтические агенты, используемые для лечения боли
EP1388538B1 (en)	2002-07-09	2010-09-01	Merck Patent GmbH	Polymerisation Initiator
US7262194B2 (en) *	2002-07-26	2007-08-28	Euro-Celtique S.A.	Therapeutic agents useful for treating pain
AU2003256922A1 (en)	2002-07-31	2004-02-16	Smithkline Beecham Corporation	Substituted heterocyclic compounds as modulators of the ccr5 receptor
US7157462B2 (en) *	2002-09-24	2007-01-02	Euro-Celtique S.A.	Therapeutic agents useful for treating pain
MXPA05003193A (es)	2002-09-27	2005-06-08	Sumitomo Pharma	Compuesto de adenina novedoso y uso del mismo.
PL377215A1 (pl) *	2002-10-17	2006-01-23	Amgen Inc.	Pochodne benzimidazolu oraz ich zastosowanie w charakterze ligandów receptora waniloidowego
US7582635B2 (en)	2002-12-24	2009-09-01	Purdue Pharma, L.P.	Therapeutic agents useful for treating pain
US7223788B2 (en)	2003-02-14	2007-05-29	Sanofi-Aventis Deutschland Gmbh	Substituted N-aryl heterocycles, process for their preparation and their use as medicaments
DE10311065A1 (de) *	2003-03-13	2004-09-23	Abbott Gmbh & Co. Kg	Pyrimidin-2-on-Verbindungen und ihre therapeutische Verwendung
EP1627869B1 (en) *	2003-05-20	2012-05-02	Ajinomoto Co., Inc.	Vanilloid receptor modulators
TWI287010B (en) *	2003-06-12	2007-09-21	Euro Celtique Sa	Therapeutic agents useful for treating pain
US7129235B2 (en) *	2003-07-11	2006-10-31	Abbott Laboratories	Amides useful for treating pain
US20050009841A1 (en) *	2003-07-11	2005-01-13	Zheng Guo Zhu	Novel amides useful for treating pain
DE602004017316D1 (de)	2003-07-24	2008-12-04	Euro Celtique Sa	Heteroaryl-tetrahydropyridylverbindungen, die sich für die behandlung bzw. die prävention von schmerzen eignen
EP1867644B1 (en)	2003-07-24	2009-05-20	Euro-Celtique S.A.	Heteroaryl-tetrahydropiperidyl compounds useful for treating or preventing pain
GEP20094676B (en) *	2003-07-24	2009-05-10	Euro Celtique Sa	Piperidine compounds and pharmaceutical compositions containing them
MXPA06001202A (es)	2003-07-29	2006-08-31	Xenon Pharmaceuticals Inc	Derivados piridilo y su uso como agentes terapeuticos.
CA2533900A1 (en)	2003-07-30	2005-02-10	Xenon Pharmaceuticals Inc.	Pyridyl derivatives and their use as therapeutic agents
CA2533897A1 (en) *	2003-07-30	2005-02-10	Xenon Pharmaceuticals Inc.	Pyridazine derivatives and their use as therapeutic agents
US7456180B2 (en) *	2003-07-30	2008-11-25	Xenon Pharmaceuticals Inc.	Piperazine derivatives and their use as therapeutic agents
US7759348B2 (en) *	2003-07-30	2010-07-20	Xenon Pharmaceuticals Inc.	Pyridazine derivatives and their use as therapeutic agents
US7754711B2 (en) *	2003-07-30	2010-07-13	Xenon Pharmaceuticals Inc.	Pyridazine derivatives and their use as therapeutic agents
PL1648874T3 (pl) *	2003-07-30	2012-04-30	Xenon Pharmaceuticals Inc	Pochodne piperazyny i ich zastosowanie jako środków leczniczych
WO2005016910A1 (ja) *	2003-08-18	2005-02-24	Sankio Chemical Co., Ltd.	ピリジルテトラヒドロピリジン類およびピリジルピペリジン類とそれらの製造方法
WO2005037284A1 (en)	2003-10-15	2005-04-28	Pfizer Products Inc.	Sorbitol dehydrogenase inhibitor and hypertensive agent combinations
EP1680431A1 (en) *	2003-10-17	2006-07-19	Rigel Pharmaceuticals, Inc.	Benzothiazole and thiazole'5,5-b!pyridine compositions and their use as ubiquitin ligase inhibitors
GB0325287D0 (en)	2003-10-29	2003-12-03	Merck Sharp & Dohme	Therapeutic agents
MY145822A (en) *	2004-08-13	2012-04-30	Neurogen Corp	Substituted biaryl piperazinyl-pyridine analogues
DE102004039789A1 (de) *	2004-08-16	2006-03-02	Sanofi-Aventis Deutschland Gmbh	Arylsubstituierte polycyclische Amine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
CN101084211A (zh) *	2004-09-20	2007-12-05	泽农医药公司	杂环衍生物及其作为治疗剂的用途
AU2005286647A1 (en) *	2004-09-20	2006-03-30	Xenon Pharmaceuticals Inc.	Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
BRPI0515482A (pt) *	2004-09-20	2008-07-22	Xenon Pharmaceuticals Inc	derivados heterocìclicos e seus usos como agentes terapêuticos
EP1827438B2 (en) *	2004-09-20	2014-12-10	Xenon Pharmaceuticals Inc.	Piperazin derivatives for inhibiting human stearoyl-coa-desaturase
US20060116368A1 (en) *	2004-11-29	2006-06-01	Calvo Raul R	4-Piperidinecarboxamide modulators of vanilloid VR1 receptor
GT200600046A (es) *	2005-02-09	2006-09-25		Terapia de combinacion
US20060223849A1 (en) *	2005-03-14	2006-10-05	Mjalli Adnan M	Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors
DE102005014904A1 (de)	2005-03-26	2007-02-01	Abbott Gmbh & Co. Kg	Substituierte Oxindol-Derivate, diese enthaltende Arzneimittel und deren Verwendung
FR2884516B1 (fr)	2005-04-15	2007-06-22	Cerep Sa	Antagonistes npy, preparation et utilisations
US8193206B2 (en)	2005-06-14	2012-06-05	Taigen Biotechnology Co., Ltd.	Pyrimidine compounds
US8097610B2 (en)	2005-08-26	2012-01-17	Shionogi & Co., Ltd.	Derivative having PPAR agonistic activity
EP2407459A1 (en)	2005-09-27	2012-01-18	Shionogi & Co., Ltd.	Synthetic intermediate in the production of a sulfonamide derivative having PGD2 receptor antagonistic activity
US20070155707A1 (en) *	2005-12-29	2007-07-05	Kadmus Pharmaceuticals, Inc.	Ionizable inhibitors of fatty acid amide hydrolase
AU2007207149A1 (en)	2006-01-18	2007-07-26	Siena Biotech S.P.A.	Modulators of alpha7 nicotinic acetylcholine receptors and therapeutic uses thereof
BRPI0708337A2 (pt) *	2006-02-28	2011-05-24	Helicon Therapeutics Inc	pipirazinas terapêutica como inibidores pde4
WO2007103719A2 (en) *	2006-03-03	2007-09-13	Incyte Corporation	MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME
TW200815426A (en) *	2006-06-28	2008-04-01	Astrazeneca Ab	New pyridine analogues II 333
WO2008005368A2 (en) *	2006-06-30	2008-01-10	Abbott Laboratories	Piperazines as p2x7 antagonists
WO2008013622A2 (en)	2006-07-27	2008-01-31	E. I. Du Pont De Nemours And Company	Fungicidal azocyclic amides
WO2008062276A2 (en) *	2006-11-20	2008-05-29	Glenmark Pharmaceuticals S.A.	Acetylene derivatives as stearoyl coa desaturase inhibitors
DE102006060598A1 (de) *	2006-12-21	2008-06-26	Merck Patent Gmbh	Tetrahydrobenzoisoxazole
EP2139869A2 (en) *	2007-04-13	2010-01-06	SuperGen, Inc.	Axl kinase inhibitors useful for the treatment of cancer or hyperproliferative disorders
CA2685266C (en) *	2007-04-27	2014-01-28	Purdue Pharma L.P.	Trpv1 antagonists and uses thereof for the treatment of prevention of pain, ui and ulcer, ibd, or ibs in an animal
MX2009011601A (es) *	2007-04-27	2009-11-10	Purdue Pharma Lp	Agentes terapeuticos utiles para tratar el dolor.
WO2008147864A2 (en)	2007-05-22	2008-12-04	Xenon Pharmaceuticals Inc.	Methods of using piperazine compounds in treating sodium channel-mediated diseases or conditions
US8058299B2 (en) *	2007-05-22	2011-11-15	Via Pharmaceuticals, Inc.	Diacylglycerol acyltransferase inhibitors
EP2581081A3 (en)	2007-06-01	2013-07-31	The Trustees Of Princeton University	Treatment of viral infections by modulation of host cell metabolic pathways
WO2008156610A2 (en)	2007-06-13	2008-12-24	Northeastern University	Antibiotic compounds
US20100249144A1 (en)	2007-06-28	2010-09-30	Demong Duane Eugene	Substituted piperazines as cb1 antagonists
EA201070077A1 (ru)	2007-06-29	2010-08-30	Эмори Юниверсити	Антагонисты nmda-рецепторов с нейропротективным действием
EP2185538A2 (en) *	2007-08-09	2010-05-19	Abbott Laboratories	Tetrahydropyridine carboxamide derivatives as trpvl antagonists
US7994174B2 (en) *	2007-09-19	2011-08-09	Vertex Pharmaceuticals Incorporated	Pyridyl sulfonamides as modulators of ion channels
US8138168B1 (en)	2007-09-26	2012-03-20	Takeda Pharmaceutical Company Limited	Renin inhibitors
JP2010540629A (ja)	2007-10-04	2010-12-24	メルク・シャープ・エンド・ドーム・コーポレイション	カルシウムチャネル遮断薬としての置換アリールスルホン誘導体
BRPI0820701A2 (pt)	2007-12-11	2015-06-16	Cytopathfinder Inc	Composto de carboxamida e seu uso como agonistas do receptor de quimiocina
JP2009249346A (ja)	2008-04-08	2009-10-29	Fujifilm Corp	ピリジン骨格を有する血液脳関門透過性化合物
KR101333660B1 (ko)	2008-07-21	2013-11-27	시오노기세이야쿠가부시키가이샤	치환-퀴녹살린-형 가교-피페리딘 화합물 및 그의 용도

2008
- 2008-04-25 CA CA2685266A patent/CA2685266C/en active Active
- 2008-04-25 AR ARP080101756A patent/AR066146A1/es not_active Application Discontinuation
- 2008-04-25 HR HRP20140279AT patent/HRP20140279T1/hr unknown
- 2008-04-25 JP JP2010504895A patent/JP5462784B2/ja active Active
- 2008-04-25 PL PL08737573T patent/PL2142529T3/pl unknown
- 2008-04-25 ES ES12198526T patent/ES2571533T3/es active Active
- 2008-04-25 US US12/110,212 patent/US20090176796A1/en not_active Abandoned
- 2008-04-25 RS RS20140128A patent/RS53212B/sr unknown
- 2008-04-25 MY MYPI20094480A patent/MY148657A/en unknown
- 2008-04-25 CN CN200880013834.9A patent/CN101932570B/zh active Active
- 2008-04-25 PE PE2012002000A patent/PE20130325A1/es active IP Right Grant
- 2008-04-25 EP EP08737573.9A patent/EP2142529B1/en active Active
- 2008-04-25 WO PCT/IB2008/001069 patent/WO2008132600A2/en not_active Ceased
- 2008-04-25 PE PE2008000707A patent/PE20090422A1/es active IP Right Grant
- 2008-04-25 EP EP12198526.1A patent/EP2604598B1/en active Active
- 2008-04-25 MX MX2009011600A patent/MX2009011600A/es active IP Right Grant
- 2008-04-25 ES ES08737573.9T patent/ES2453947T3/es active Active
- 2008-04-25 CA CA2833209A patent/CA2833209C/en active Active
- 2008-04-25 US US12/110,089 patent/US20090170867A1/en not_active Abandoned
- 2008-04-25 BR BRPI0809795-0A2A patent/BRPI0809795A2/pt not_active Application Discontinuation
- 2008-04-25 US US12/110,155 patent/US8476277B2/en active Active
- 2008-04-25 CA CA2756791A patent/CA2756791C/en active Active
- 2008-04-25 PT PT87375739T patent/PT2142529E/pt unknown
- 2008-04-25 KR KR1020127031094A patent/KR20130004524A/ko not_active Ceased
- 2008-04-25 AU AU2008243874A patent/AU2008243874B2/en active Active
- 2008-04-25 DK DK08737573.9T patent/DK2142529T3/da active
- 2008-04-25 ME MEP-2014-674A patent/ME02123B/me unknown
- 2008-04-25 TW TW097115334A patent/TWI362930B/zh not_active IP Right Cessation
- 2008-04-25 UY UY31050A patent/UY31050A1/es not_active Application Discontinuation
- 2008-04-25 EP EP13155157.4A patent/EP2604599A1/en not_active Withdrawn
- 2008-04-25 NZ NZ580266A patent/NZ580266A/en unknown
- 2008-04-25 KR KR1020097024875A patent/KR20100005725A/ko not_active Ceased
2009
- 2009-10-22 IL IL201688A patent/IL201688A/en active IP Right Grant
- 2009-11-17 CO CO09130337A patent/CO6241153A2/es active IP Right Grant
2012
- 2012-02-14 US US13/396,450 patent/US8575199B2/en active Active
2013
- 2013-03-28 US US13/852,913 patent/US8889690B2/en active Active
- 2013-04-02 IL IL225521A patent/IL225521A0/en unknown
- 2013-04-26 PH PH12013500848A patent/PH12013500848B1/en unknown
- 2013-07-29 JP JP2013156236A patent/JP2014015465A/ja active Pending
2014
- 2014-03-24 CY CY20141100230T patent/CY1115262T1/el unknown
- 2014-09-26 US US14/498,724 patent/US9365563B2/en active Active
2016
- 2016-06-10 US US15/179,612 patent/US9878991B2/en active Active
2018
- 2018-01-08 US US15/864,750 patent/US10584110B2/en active Active

Also Published As

Publication number	Publication date
BRPI0809795A2 (pt)	2014-10-07
AR066146A1 (es)	2009-07-29
PE20090422A1 (es)	2009-04-18
CA2756791C (en)	2016-09-13
PT2142529E (pt)	2014-03-20
US9878991B2 (en)	2018-01-30
US8476277B2 (en)	2013-07-02
US9365563B2 (en)	2016-06-14
RS53212B (sr)	2014-08-29
MY148657A (en)	2013-05-15
US8575199B2 (en)	2013-11-05
IL201688A0 (en)	2010-05-31
JP2014015465A (ja)	2014-01-30
EP2142529B1 (en)	2013-12-25
CA2685266A1 (en)	2008-11-06
ES2453947T3 (es)	2014-04-09
DK2142529T3 (da)	2014-02-10
PH12013500848A1 (en)	2015-05-18
CY1115262T1 (el)	2017-01-04
US20120177570A1 (en)	2012-07-12
UY31050A1 (es)	2008-07-03
IL225521A0 (en)	2013-06-27
HRP20140279T1 (hr)	2014-04-25
HK1184152A1 (en)	2014-01-17
US20160355499A1 (en)	2016-12-08
AU2008243874A1 (en)	2008-11-06
JP2010525048A (ja)	2010-07-22
EP2142529A2 (en)	2010-01-13
PL2142529T3 (pl)	2014-06-30
TWI362930B (en)	2012-05-01
CA2685266C (en)	2014-01-28
EP2604599A1 (en)	2013-06-19
US20150018366A1 (en)	2015-01-15
IL201688A (en)	2017-01-31
CA2833209C (en)	2016-06-28
TW200911249A (en)	2009-03-16
US10584110B2 (en)	2020-03-10
CN101932570A (zh)	2010-12-29
MX2009011600A (es)	2010-11-26
PE20130325A1 (es)	2013-03-18
ME02123B (me)	2014-08-29
US20090170867A1 (en)	2009-07-02
JP5462784B2 (ja)	2014-04-02
HK1139949A1 (en)	2010-09-30
US20090176796A1 (en)	2009-07-09
CA2833209A1 (en)	2013-11-13
WO2008132600A2 (en)	2008-11-06
KR20130004524A (ko)	2013-01-10
US20090170868A1 (en)	2009-07-02
EP2604598A1 (en)	2013-06-19
KR20100005725A (ko)	2010-01-15
US20130338170A1 (en)	2013-12-19
CA2756791A1 (en)	2008-11-06
WO2008132600A3 (en)	2009-03-12
AU2008243874B2 (en)	2012-01-19
EP2604598B1 (en)	2016-04-06
CO6241153A2 (es)	2011-01-20
CN101932570B (zh)	2014-11-26
NZ580266A (en)	2012-03-30
ES2571533T3 (es)	2016-05-25
US8889690B2 (en)	2014-11-18
US20180208575A1 (en)	2018-07-26

Publication	Publication Date	Title
PH12013500848B1 (en)	2015-05-18	Trpv1 antagonists and uses thereof
PH12013500913A1 (en)	2019-01-14	Substituted-quinoxaline-type-piperidine compounds and the uses thereof
MX2009011601A (es)	2009-11-10	Agentes terapeuticos utiles para tratar el dolor.
UA95644C2 (ru)	2011-08-25	Пиридазиноновые производные, фармацевтическая композиция и способ лечения заболеваний
GEP20146146B (en)	2014-08-25	Pyrrolopyrimidine compounds as inhibitors of cdk4/6
MA32508B1 (fr)	2011-07-03	Composes organiques
MY153915A (en)	2015-04-15	Organic compounds
EA201100750A1 (ru)	2011-12-30	Замещенные диоксопиперидинилфталимидные производные
MX2011012366A (es)	2011-12-08	Mezclas fungicidas sinergeticas.
MX2010008713A (es)	2010-09-09	Derivados de 5,6-bisaril-2-piridina-carboxamida, su preparacion y su aplicacion en terapeutica como antagonistas de los receptores de la urotensina ii.
MY153948A (en)	2015-04-15	Substituted-quinoxaline-type bridged-piperidine compounds and the uses thereof
PH12012501813A1 (en)	2012-12-10	Iap bir domain binding compounds
EA201001747A1 (ru)	2011-08-30	Бензоксазиноновые производные, действующие в качестве агониста бета-2-адренорецептора, для лечения респираторных расстройств
EA201171339A1 (ru)	2012-05-30	Способ снижения внутриглазного давления у людей
EP2585446A4 (en)	2013-12-25	COMPOUNDS HAVING ANTAGONIST ACTIVITY OF TRPV1 AND USES THEREOF
MX2010006787A (es)	2010-10-04	Análogos halogenados de agentes anti-fibroticos.
WO2014102594A3 (en)	2014-10-16	Substituted benzimidazole-type piperidine compounds and uses thereof
WO2014102592A3 (en)	2014-10-16	Oxime/substituted quinoxaline-type piperidine compounds and uses thereof
NO20085317L (no)	2009-02-05	Imidazoazepinonforbindelser
MY185061A (en)	2021-04-30	Trpv1 antagonists including dihydroxy substituent and uses thereof
MY152040A (en)	2014-08-15	Triazolopyridazines as par1 inhibitors, production thereof, and use as medicaments
WO2014020405A8 (en)	2015-01-15	Cyclic urea- or lactam-substituted quinoxaline-type piperidine compounds and the uses thereof
MY148732A (en)	2013-05-31	Triazolium salts as par1 inhibitors, production thereof, and use as medicaments
TW200800993A (en)	2008-01-01	Organic compounds
MX2009005242A (es)	2009-08-19	Derivados de 3-(hetero)arilisoquinolinamida sustituida en posición 5, 6 o 7 y uso terapeutico del mismo.